Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

Stopped early · Phase 4

Conditions studied: Anemia

In brief

The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.

Key facts

Study ID

NCT01737879

Run by

Amgen

People needed

41

Starts

2012-10-01

Expected to finish

2013-07-01

Last updated by the study team

2014-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Phoenix, Arizona, United States
• Research Site — Tempe, Arizona, United States
• Research Site — Azusa, California, United States
• Research Site — Bakersfield, California, United States
• Research Site — Granada Hills, California, United States
• Research Site — Los Angeles, California, United States
• Research Site — Lynwood, California, United States
• Research Site — Paramount, California, United States
• Research Site — Riverside, California, United States
• Research Site — Whittier, California, United States
• Research Site — Orange, Connecticut, United States
• Research Site — Meridian, Idaho, United States
• Research Site — Kansas City, Missouri, United States
• Research Site — Bayonne, New Jersey, United States
• Research Site — Amherst, New York, United States
• Research Site — Yonkers, New York, United States
• Research Site — Winston-Salem, North Carolina, United States
• Research Site — Oklahoma City, Oklahoma, United States
• Research Site — Orangeburg, South Carolina, United States
• Research Site — Dyersburg, Tennessee, United States
• Research Site — Jackson, Tennessee, United States
• Research Site — Houston, Texas, United States
• Research Site — Chesapeake, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.